Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists explore GLUT1 protein as a diagnostic clue for rare lung tumors

NCT ID NCT03645915

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than current methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If GLUT1 staining proves reliable, it could become a new diagnostic tool to help classify lung neuroendocrine tumors.
What could go wrong
This is a small, early study (36 samples) looking at a diagnostic marker, not a treatment. The findings need much larger studies to confirm if GLUT1 is truly useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

36 people

The number who actually took part.

Started

Jan 2014

Finished

Nov 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Between 2009 and 2014, 36 consecutive patients underwent a surgical resection or biopsy of pulmonary neuroendocrine tumor at University Hospital of Amiens: 5 cases of atypical carcinoid tumor; 13 cases of typical carcinoid tumor; 8 cases of small cell neuroendocrine carcinoma; and 10 cases of large cell neuroendocrine carcinoma. Clinical data were obtained from retrospective review of medical records: population characteristics (age, gender) and tumor size

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with neuroendocrine tumors Exclusion Criteria: * Patients without neuroendocrine tumors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung neuroendocrine tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease lung neoplasm lung neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung tumor

Contacts and locations

Locations

  • CHU Amiens-Picardie

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.